Expression of BRAF V600E in Tissue Samples of Colorectal Carcinoma and Its Correlation with Various Clinico-Pathological Parameters
DOI:
https://doi.org/10.51985/JBUMDC2020057Keywords:
BRAF V600E Immunohistochemistry, Colorectal cancer, Clinicopathological parameters.Abstract
various clinico-pathological parameters.
Study design and setting: Cross-sectional study was conducted at department of Pathology, Pakistan Navy Station Shifa
hospital Karachi from 1st March 2016 to 28th February 2019
Methodology: Total of 51 cases of colorectal cancer were analyzed for immunohistochemical staining using BRAF
antibodies on representative tissue blocks. Clinical and pathological records were retrieved for data collection. The results
of immunohistochemical analysis were correlated with the recorded clinico-pathological parameters.
Results: In this study 51 cases of colorectal cancer were analyzed for immune expression of BRAF V600E. The age of
the patients ranged from 14 to 85 years with the mean age of 60.96 years. Among the 51 cases, 37(72.5%) cases were males
and 14(27.4%) were females. 37(72.5%) were localized to left side colon and 14(27.4%) were found in the right colon.
For BRAF V600E, positive expression was seen in 20(39.2%) cases, whereas 31(60.7%) cases showed negative expression
of BRAFV600E. No significant association was seen between BRAF V600E expression and histological variants like age,
gender, tumor location and glandular carcinomas.
Conclusion: BRAF V600E immunosuppression was seen in 39.2% of colorectal carcinoma in this study. No significant
association was seen in BRAF V600E expression and histological variants.
References
Springer, Cham. Pollett A. Colorectal Carcinoma. InAtlas of Intestinal Pathology 2019 (pp. 15-25). Springer, Cham.
Zdravkovic N et al. Serum levels of immunosuppressive cytokines and tumor markers in metastatic colorectal carcinoma. Journal of BUON. 2017;22:1-8.
Zeng J, Tang ZH, Liu S, Guo SS. Clinicopathological significance of overexpression of interleukin-6 in colorectal cancer. World journal of gastroenterology. 2017 Mar 14;23(10):1780.
Hohenberger W. Colorectal cancer–heading to the future. Innovative Surgical Sciences. 2018 Mar 9;3(1):1-2.
Mármol I, Sánchez-de-Diego C, Pradilla Dieste A, Cerrada E, Rodriguez Yoldi MJ. Colorectal carcinoma: a general overview and future perspectives in colorectal cancer. International journal of molecular sciences. 2017 Jan; 18(1):197.
Patel SG, Ahnen DJ. Colorectal cancer in the young. Current gastroenterology reports. 2018 Apr 1; 20(4):15.
Nikolouzakis TK et al. Improving diagnosis, prognosis and prediction by using biomarkers in CRC patients. Oncology Reports. 2018 Jun 1; 39(6):2455-72.
Liu SL, Cheung WY. Role of surveillance imaging and endoscopy in colorectal cancer follow-up: Quality over quantity. World Journal of Gastroenterology. 2019 Jan 7; 25(1):59.
Haley L et al. Performance characteristics of next-generation sequencing in clinical mutation detection of colorectal cancers. Modern Pathology. 2015 Oct;28(10):1390-9.
Loupakis F, Moretto R, Aprile G, Muntoni M, Cremolini C, Iacono D, Casagrande M, Ferrari L, Salvatore L, Schirripa M, Rossini D. Clinico-pathological nomogram for predicting BRAF mutational status of metastatic colorectal cancer. British journal of cancer. 2016 Jan;114(1):30-6.
Gómez-España MA et al. SEOM clinical guidelines for diagnosis and treatment of metastatic colorectal cancer (2018). Clinical and Translational Oncology. 2019 Jan 25;21(1):46-54.
González-Colunga KJ, Lino-Silva LS, Salcedo-Hernández RA, Ruiz-García EB, Zepeda-Najar C. BRAF V600E expression by immunohistochemistry in colon cancer and clinico-pathologic features associated with BRAF-mutated colonic cancers in Mexican patients. Journal of Gastrointestinal Cancer. 2020 Mar; 51(1):35-40.
Kwon JH, Jeong BK, Yoon YS, Yu CS, Kim J. Utility of BRAF VE1 immunohistochemistry as a screening tool for colorectal cancer harboring BRAF V600E mutation. Journal of pathology and translational medicine. 2018 May;52(3):157-163.
Vakiani E, Yaeger R, Brooke S, Zhou Y, Klimstra DS, Shia J. Immunohistochemical detection of the BRAF V600E mutant protein in colorectal neoplasms. Applied immunohistochemistry & molecular morphology: AIMM/official publication of the Society for Applied Immunohistochemistry. 2015 Jul; 23(6):438-443.
Schafroth C, Galván JA, Centeno I, Koelzer VH, Dawson HE, Sokol L, Rieger G, Berger MD, Hädrich M, Rosenberg R, Nitsche U. VE1 immunohistochemistry predicts BRAF V600E mutation status and clinical outcome in colorectal cancer. Oncotarget. 2015 Dec 8;6(39):41453-41463.
Hussain M, Waqas O, Hassan U, Loya A, Akhtar N, Mushtaq S, Yusuf MA, Syed AA. Right-sided and left-sided colon cancers are two distinct disease entities: an analysis of 200 cases in Pakistan. Asian Pac J Cancer Prev. 2016; 17(5):2545-8.
Zahir MN, Azhar EM, Rafiq S, Ghias K, Shabbir-Moosajee M. Clinical features and outcome of sporadic colorectal carcinoma in young patients: a cross-sectional analysis from a developing country. International Scholarly Research Notices. 2014;2014.
Tsai YJ, Huang SC, Lin HH, Lin CC, Lan YT, Wang HS, Yang SH, Jiang JK, Chen WS, Lin TC, Lin JK. Differences in gene mutations according to gender among patients with colorectal cancer. World journal of surgical oncology. 2018 Dec 1; 16(1):128-132
Elsabah, M. T., & Adel, I. (2013). Immunohistochemical assay for detection of K-ras protein expression in metastatic colorectal cancer. Journal of the Egyptian National Cancer Institute, 25(1), 51-56.
Dvorak K, Higgins A, Palting J, Cohen M, Brunhoeber P. Immunohistochemistry with Anti-BRAF V600E (VE1) mouse monoclonal antibody is a sensitive method for detection of the BRAF V600E mutation in colon cancer: Evaluation of 120 cases with and without KRAS mutation and literature review. Pathology & Oncology Research. 2019 Jan 15; 25(1):349-59.
González-Colunga KJ, Lino-Silva LS, Salcedo-Hernández RA, Ruiz-García EB, Zepeda-Najar C. BRAF V600E expression by immunohistochemistry in colon cancer and clinico-pathologic features associated with BRAF-mutated colonic cancers in Mexican patients. Journal of Gastrointestinal Cancer. 2020 Mar; 51(1):35-40.
Mesteri I, Bayer G, Meyer J, Capper D, Schoppmann SF, Von Deimling A, Birner P. Improved molecular classification of serrated lesions of the colon by immunohistochemical detection of BRAF V600E. Modern Pathology. 2014 Jan; 27(1):135-44.
Chen D, Huang JF, Liu K, Zhang LQ, Yang Z, Chuai ZR, Wang YX, Shi DC, Huang Q, Fu WL. BRAF V600E mutation and its association with clinicopathological features of colorectal cancer: a systematic review and meta-analysis. PloS one. 2014 Mar 3; 9(3):e90607.
Lasota J et al. Detection of the BRAF v600e mutation in colon carcinoma–critical evaluation of the imunohistochemical approach. The American journal of surgical pathology. 2014 Sep; 38(9):1235-1241.
Cantwell-Dorris ER, O'Leary JJ, Sheils OM. BRAFV600E: implications for carcinogenesis and molecular therapy. Molecular cancer therapeutics. 2011 Mar 1; 10(3):385-94.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2021 Hina Wasti, Summayyah Shawana, Beenish Hussain, Santosh Kumar Sidhwani, Rubbab Mir, Hareem Fatima
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Journal of Bahria University Medical & Dental College is an open access journal and is licensed under CC BY-NC 4.0. which permits unrestricted non commercial use, distribution and reproduction in any medium, provided the original work is properly cited. To view a copy of this license, visit https://creativecommons.org/licenses/by-nc/4.0 
